Inhibiting both autophagy and NRF2 signalling simultaneously can increase the cytotoxic effects of cisplatin, diminish the proliferation of oral CD44+ cells and provide new possibilities for addressing chemoresistance and tumour recurrence related to oral cancer CSCs in clinical practice.76 Here, CD44 is linked to neoplasm.